Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn’s & Colitis O...
July 07 2021 - 7:01AM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on discovering, acquiring,
developing and commercializing therapeutics in the disease areas of
immunology, inflammation and oncology, today announced that it will
present data related to GB004 at the 2021 Virtual Congress of the
European Crohn’s and Colitis Organisation (ECCO), to be held
virtually from July 2-3 and 8-10. On July 8, William Sandborn,
M.D., will present a digital oral presentation, which will include
target engagement and pharmacodynamic biomarker data from the
completed GB004 Phase 1b clinical trial in patients with
mild-to-moderate ulcerative colitis.
Details for presentations related to GB004, an oral,
gut-target HIF-1α stabilizer, are as follows:
Digital Oral Presentation Title: Target Engagement and
Pharmacodynamic Biomarker Analysis following Treatment with the
Oral Gut-Targeted HIF-1α Stabilizer GB004 in a Phase 1b Trial in
Active Ulcerative Colitis Presenting Author: William
Sandborn, M.D. Date: Thursday, July 8, 2021 Session
Title: DOP Session 1 - Molecular Profiling Presentation
Code: DOP05 Presentation Time: 8:10 – 8:15 a.m. PDT /
11:10 – 11:15 a.m. EDT / 5:10 – 5:15 p.m. CEST
ePoster Title: GB004 Drives Protective Effects on Immune
Cells and Epithelial Cells Using Human Ex Vivo Monolayer and
Co-Culture Systems Poster Code: P059
The presentation and poster can be accessed on the ECCO website.
The presentation and poster will also be made available in the
“Posters and Publications” section of the Gossamer Bio website at
gossamerbio.com, after the conclusion of the Virtual Congress.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on discovering, acquiring, developing and commercializing
therapeutics in the disease areas of immunology, inflammation and
oncology. Its goal is to be an industry leader in each of these
therapeutic areas and to enhance and extend the lives of patients
suffering from such diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210707005256/en/
For Investors and Media: Bryan Giraudo, Chief Financial
Officer Gossamer Bio Investor Relations ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Sep 2023 to Sep 2024